Indy Sawhney’s Post

Nothing is more personal than Health Care. Whilst Generative AI (GenAI) offers a dramatic increase in efficiency and #ValueCreation, it also poses significant challenges. As tech-driven shifts disrupt existing health care models, new #DigitalCapabilities must be a core part of strategy. Emerging technologies such as GenAI will not replace the doctor-patient relationship, but it will make doctors along with pharmaceutical companies, MedTech players, and other health care organizations even better at what they do. Complexity and constraints can be #Catalysts for invention, but biopharma industry leaders must prioritize use cases that have clear, measurable goals. The latest #Breakthroughs in technology have already led to big reductions in drug research and development. GenAI can be applied at all stages of the value chain—operations, commercial and medical affairs, and corporate functions, in addition to R&D—with the potential to substantially increase efficiency and effectiveness by #Transforming existing processes. Realizing value from GenAI is not automatic. It takes careful assessment, planning, and implementation. One approach is to select two or three functions and business units to serve as test beds for initial GenAI solutions and #ChangeManagement practices before scaling them more widely. Senior management should also identify “believers” in various functions who will help drive the change, especially if it is implemented from the top. Management can conduct a #TalentAssessment to identify GenAI Champions” who will lead initiatives, staff teams, and recruit others to the cause. To get the most from GenAI, companies need enterprise-wide infrastructure and #Platforms that give people access to the tools and give the tools access to data. Biopharma companies will have to make platform choices that span the entire Tech Stack, including secure cloud infrastructure, data platforms, models, and applications. To achieve maximum impact, GenAI also needs to be #Integrated with existing AI tools that can enable rapid experimentation. Nvidia, for example, is offering a set of generative AI cloud services that enable customization of AI #FoundationModels to accelerate drug discovery and research in genomics, chemistry, biology, and molecular dynamics. A number of startups and incumbents have embraced the service, but each company needs to look at such offerings in light of whether its own internal unstructured data confers a #CompetitiveAdvantage. To improve your Business or Industry - #Value Creation and Realization capabilities, follow me and contact us: https://lnkd.in/dDf6v5GZ. Also learn more by following our Business Pages #TMTdigtal at: https://lnkd.in/ersCKxQy and #TMTCrossCare at: https://lnkd.in/gVKaW4cj. #MedTechAI #ValueRealization #Leadership #Strategy #Transformation #DigitalBusiness #Partnership

Nothing is more personal than Health Care. Whilst Generative AI (GenAI) offers a dramatic increase in efficiency and #ValueCreation, it also poses significant challenges. As tech-driven shifts disrupt existing health care models, new #DigitalCapabilities must be a core part of strategy. Emerging technologies such as GenAI will not replace the doctor-patient relationship, but it will make doctors along with pharmaceutical companies, MedTech players, and other health care organizations even better at what they do. Complexity and constraints can be #Catalysts for invention, but biopharma industry leaders must prioritize use cases that have clear, measurable goals. The latest #Breakthroughs in technology have already led to big reductions in drug research and development. GenAI can be applied at all stages of the value chain—operations, commercial and medical affairs, and corporate functions, in addition to R&D—with the potential to substantially increase efficiency and effectiveness by #Transforming existing processes. Realizing value from GenAI is not automatic. It takes careful assessment, planning, and implementation. One approach is to select two or three functions and business units to serve as test beds for initial GenAI solutions and #ChangeManagement practices before scaling them more widely. Senior management should also identify “believers” in various functions who will help drive the change, especially if it is implemented from the top. Management can conduct a #TalentAssessment to identify GenAI Champions” who will lead initiatives, staff teams, and recruit others to the cause. To get the most from GenAI, companies need enterprise-wide infrastructure and #Platforms that give people access to the tools and give the tools access to data. Biopharma companies will have to make platform choices that span the entire Tech Stack, including secure cloud infrastructure, data platforms, models, and applications. To achieve maximum impact, GenAI also needs to be #Integrated with existing AI tools that can enable rapid experimentation. Nvidia, for example, is offering a set of generative AI cloud services that enable customization of AI #FoundationModels to accelerate drug discovery and research in genomics, chemistry, biology, and molecular dynamics. A number of startups and incumbents have embraced the service, but each company needs to look at such offerings in light of whether its own internal unstructured data confers a #CompetitiveAdvantage. To improve your Business or Industry - #Value Creation and Realization capabilities, follow me and contact us: https://lnkd.in/dDf6v5GZ. Also learn more by following our Business Pages #TMTdigtal at: https://lnkd.in/ersCKxQy and #TMTCrossCare at: https://lnkd.in/gVKaW4cj. #MedTechAI #ValueRealization #Leadership #Strategy #Transformation #DigitalBusiness #Partnership

Healthcare investment in generative AI has just begun!! 💡 Generative artificial intelligence (AI) is gaining popularity in healthcare, promising both efficiency and creativity. It incorporates technologies such as large language models (LLMs) and foundation models. Providers are implementing generative AI to improve patient documentation and communication. Generative AI aids biomedical research by expediting medication development and predictive modeling. Payers use it for member navigation, and medtech businesses invest in AI-powered diagnostic equipment. Healthcare investment in generative AI is increasing, with large tech companies partnering with healthcare organizations. Hippocratic AI and Genesis Therapeutics are among the firms backed by venture capital funds. Mature organizations are also investing in LLMs to boost operational efficiency. Investors must assess generative AI's influence on portfolio companies and consider using commercially available tools or developing bespoke software. The long-term promise is to improve labour efficiency and clinical outcomes while also altering healthcare workflows. Consideration of generative AI's consequences can result in profits and drive the healthcare revolution. 🔗  #HealthcareAI #FutureofHealthcare #AIInvestment #InnovativeHealthcare #AIinMedicine #TechHealthcare #HealthcareTrends  

Transforming Healthcare With Generative AI 🤖 📌Generative AI holds the potential to enhance productivity, elevate patient and provider satisfaction, and enhance clinical results. Moreover, It can reduce administrative burdens, accelerate advancements in biomedical research and drug discovery, optimize claims processing, and facilitate the creation of advanced diagnostic tools. 📌Venture capital and growth equity funds are investing heavily in companies specializing in generative AI. Mature private equity-backed firms are leveraging large language models (LLMs) to enhance operational efficiency. Investors recognize the potential of generative AI and LLMs to revolutionize healthcare, leading to significant capital deployment in companies driving innovation in this space. 📌Companies relying on creative content generation or labor-intensive tasks face higher disruption risks, while those in healthcare may see opportunities for democratized access. When deploying generative AI, investors should identify opportunities for leveraging existing tools, consider building proprietary software, and establish governance protocols. What do you think? 💬 👉Here you can download the full report: https://lnkd.in/dz2AWnjf #GenAI #Healthcare

Leverage Generative AI to foster equity in Healthcare & Life-sciences- A look at the possibilities: As the industry works on technical feasibility vs. value recognized the market of Gen AI in #HCLS is projected to grow by 85 % from its current valuation of $1B to $22B by end of 2027 (source: https://www.bcg.com) #genai to soon emerge as a key tool for healthcare & hospital systems to boost productivity, free critical resources from mundane tasks and reduce administrative burdens of a whopping $1 trillion. (source: https://lnkd.in/eXcq4Ksz) These burdens affect patients ranging from their reduced access to health care to subsequent effects of their mental wellbeing. Citi Global Insights (CGI) predicts 25-30% of admin cost savings with AI adoption. This can benefit the staff and they will pass it as improved patient experience. Other areas where AI will benefit is diagnostics, critical assessment of populations, optimizing drug development and evaluation. The recent FDA acceptance to algorithmic drug development pilot tool expedites availability of safe and effective treatments at scale. (Refer: https://lnkd.in/e2Tpwykq) Opportunities of maximum value realization Commercial and Medical Affairs 1. Patient & Physician customer journey orchestration 2. HCP Engagement through content classification 3. Patient Doctor Case summarization 4. Automated Customer Service 5. Real world Evidence Generation 6. Voice Assistants, Human Robots & Conversational AI 7. Localizations & Translations Research & Development 1. Discovery of new compounds, Protein & Molecule Generation for Drug Development 2. Synthetic generation of Healthcare assets 3. Self Service Data Analytics tools & services Pharma Manufacturing & Supply Chain 1. Resource / Material forecasting 2. Inventory Management & Intelligent Tracking 3. Automated Logistics Management 4. Operations Excellence Clinical Trials and Operations 1. Patient Outreach & Recruitment 2. Federated knowledge sharing 3. Self-serve onboarding 4. Protocol Generation & Optimization 5. Patient Support Services Quality Control & Surveillance 1. Deviations Management 2. Product Quality Reporting & Analysis 3. Staff productivity & Quality Review optimization 4. Standard operating procedures review management This interesting correlation between increased equity & diversity in the care continuum and adoption of Generative AI across the value chain will be fast tracked with patients, care givers and clinicians asking for more value for less cost & effort. #healthcareequity #aiadoption #clinicaldecisionsupport #patientcentricity #customerexperience

💡 💊 Unconventional Wisdom for Generative AI Adoption in Healthcare and Life Sciences As generative AI reshapes healthcare and life sciences, organizations must adopt innovative strategies to stay ahead. Here are some unconventional approaches to consider: 1. 🔄 Embrace Failures: Learn from unsuccessful AI experiments by treating them as opportunities for improvement and refining your approach. As such, experimenting with use cases that are internal are better bets because you get to control the environment and experience. Also, if you are not failing, you are not trying hard enough :) 2. 🤝 Foster Collaboration Beyond Borders: Partner with diverse stakeholders, such as academia, startups, and international organizations, to drive AI-led innovation. Also, collaborate across LOBs (lines of businesses) to encourage cross-pollination of ideas/thoughts. Organize internal hackathons, and events with technology partners to help level-up your teams through relevant technical sessions and through industry specific demos to showcase the art of the possible. 3. 💡 Incentivize Employee-Driven AI Projects: Encourage bottom-up innovation by providing resources and support for employee-driven initiatives. Set up controlled environments with sample multi-modal data that employees can leverage to build their demos/experiments. Make available multiple LLMs (both commercial and open source) for them to experiment with and better understand how these LLMs compare/perform in various healthcare and life sciences scenarios. Remember to set monthly experiment budgets to prevent budget dilution and IAM policies to ensure access to approved sample data, LLMs, and other cloud resources at this phase. By adopting unconventional strategies, organizations in the healthcare and life sciences sectors can maximize the potential of generative AI and drive transformative change. Talk to your AWS Account team for help on how to get started on setting up Generative AI environment for your employees, organize hackathons, immersion days, product/service demos, and embarking on your generative AI acceleration journey! 💬 Share your innovative ideas for adopting AI in your organization below! #GenerativeAI #HealthcareInnovation #pharmaceutical #biopharma #biotech #aws #AmazonBedrock #ChangeManagement #innovation #genai #lifesciences #healthcare #patientcare #ai #clinicalresearch #clinicaltrial #partnership #aiadoption #coe #ai #customersuccess

An interesting article discusses the ongoing transformation in the pharmaceutical industry with the adoption of generative artificial intelligence (AI). Key points: 💊 Pharma's AI Revolution is in Full Swing! 40% of companies are banking on AI savings in their 2024 budgets. 🚀 🧠 From boosting productivity to saving time, generative AI is making waves in biomedical review, preclinical research, competitive intelligence and more! 🌐 🌟 To successfully scale generative AI, companies should prioritize high-return use cases, establish strong internal leadership, build foundational support, reshape talent strategy, forge strategic partnerships, and engage in ethical considerations 🚀 Follow the 3 C's: Choose Wisely, Champion Change, and Craft Your AI Destiny with DataZymes #AIinPharma #competitiveintelligence #PharmaInnovation #AIRevolution #ScaleWithStrategy

I just came across this insightful article discussing how AI and automation are revolutionizing the life sciences industry. The integration of cutting-edge technology is propelling the enterprise modernization journey to new heights. From drug discovery to clinical trials, AI is streamlining processes and accelerating innovation. This promises to bring more effective treatments to patients faster than ever before. #𝗹𝗶𝗳𝗲𝘀𝗰𝗶𝗲𝗻𝗰𝗲𝘀 #𝗔𝗜 #𝗵𝗲𝗮𝗹𝘁𝗵𝗰𝗮𝗿𝗲𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 #𝗱𝗶𝗴𝗶𝘁𝗮𝗹𝘁𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 https://lnkd.in/eirqR7tq

Managing data from 100-150 drug discovery experiments is extremely challenging. Generative AI is the answer. It simplifies the process, creating comprehensive experiment summaries and reports, and boosting efficiency for your dedicated researchers. Learn more in our latest white paper: https://lnkd.in/d4MbQpwE #EngineeringExcellence #PrepareToGrow #AI #EntepriseAI #Pharma

Rock Health's piece on use cases for AI is a short and insightful read. It will get you thinking in a more disciplined way about how to harness the power of these tools. While the article is focused on Pharma, the structure and thought process are broadly applicable. https://lnkd.in/gqxU6tRC